Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPCH NYSE:PACS NASDAQ:RDNT NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPCHOption Care Health$20.51-1.2%$28.29$18.01▼$36.80$3.26B0.683.59 million shs4.30 million shsPACSPACS Group$33.59-0.1%$34.37$7.50▼$43.08$5.29B-0.03706,751 shs542,525 shsRDNTRadNet$58.19+1.2%$60.26$50.76▼$85.84$4.50B1.43775,574 shs1.46 million shsVRDNViridian Therapeutics$16.61-2.3%$21.57$12.07▼$34.29$1.75B0.823.17 million shs4.37 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPCHOption Care Health+1.47%+2.07%-25.20%-38.97%-37.95%PACSPACS Group-0.56%+0.06%+3.80%-12.82%+219.74%RDNTRadNet-1.94%+1.68%+5.35%-16.96%+4.80%VRDNViridian Therapeutics-3.05%+26.08%+21.75%-41.89%+38.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPCHOption Care Health$20.51-1.2%$28.29$18.01▼$36.80$3.26B0.683.59 million shs4.30 million shsPACSPACS Group$33.59-0.1%$34.37$7.50▼$43.08$5.29B-0.03706,751 shs542,525 shsRDNTRadNet$58.19+1.2%$60.26$50.76▼$85.84$4.50B1.43775,574 shs1.46 million shsVRDNViridian Therapeutics$16.61-2.3%$21.57$12.07▼$34.29$1.75B0.823.17 million shs4.37 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPCHOption Care Health+1.47%+2.07%-25.20%-38.97%-37.95%PACSPACS Group-0.56%+0.06%+3.80%-12.82%+219.74%RDNTRadNet-1.94%+1.68%+5.35%-16.96%+4.80%VRDNViridian Therapeutics-3.05%+26.08%+21.75%-41.89%+38.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPCHOption Care Health 2.83Moderate Buy$31.2552.36% UpsidePACSPACS Group 3.00Buy$44.4032.20% UpsideRDNTRadNet 2.90Moderate Buy$88.1451.47% UpsideVRDNViridian Therapeutics 2.79Moderate Buy$37.31124.61% UpsideCurrent Analyst Ratings BreakdownLatest VRDN, PACS, RDNT, and OPCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026OPCHOption Care Health Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.005/6/2026VRDNViridian Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $34.005/6/2026OPCHOption Care Health Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/5/2026VRDNViridian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.005/4/2026OPCHOption Care Health JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $33.005/1/2026OPCHOption Care Health Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.005/1/2026OPCHOption Care Health Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $32.005/1/2026OPCHOption Care Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $39.005/1/2026OPCHOption Care Health StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.005/1/2026OPCHOption Care Health Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.005/1/2026OPCHOption Care Health TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$37.00 ➝ $23.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPCHOption Care Health$5.65B0.57$2.02 per share10.16$8.60 per share2.38PACSPACS Group$5.29B1.00$1.60 per share21.04$6.08 per share5.52RDNTRadNet$2.04B2.23$3.26 per share17.84$17.58 per share3.31VRDNViridian Therapeutics$70.85M24.16N/AN/A$4.89 per share3.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPCHOption Care Health$207.59M$1.2915.9011.031.143.64%18.17%7.16%N/APACSPACS Group$191.54M$1.2327.3113.761.033.62%22.55%3.45%5/11/2026 (Confirmed)RDNTRadNet-$18.65M-$0.25N/A53.88N/A-0.91%2.52%0.88%5/10/2026 (Estimated)VRDNViridian Therapeutics-$342.60M-$3.32N/AN/AN/A-490.31%-80.19%-48.84%N/ALatest VRDN, PACS, RDNT, and OPCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026PACSPACS Group$0.42N/AN/AN/A$1.36 billionN/A5/10/2026Q1 2026RDNTRadNet-$0.1643N/AN/AN/A$557.93 millionN/A5/5/2026Q1 2026VRDNViridian Therapeutics-$1.06-$0.90+$0.16-$0.90$0.04 million$0.14 million4/30/2026Q1 2026OPCHOption Care Health$0.37$0.40+$0.03$0.29$1.39 billion$1.35 billion3/2/2026Q4 2025RDNTRadNet$0.19$0.23+$0.04-$0.01$515.67 million$547.71 million2/26/2026Q4 2025VRDNViridian Therapeutics-$0.90-$1.08-$0.18-$1.08$15.75 million$0.13 million2/24/2026Q4 2025OPCHOption Care Health$0.46$0.46N/A$0.37$1.46 billion$1.47 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthOPCHOption Care HealthN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPCHOption Care Health0.851.641.07PACSPACS Group0.361.071.07RDNTRadNet0.791.761.76VRDNViridian Therapeutics0.1015.1512.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPCHOption Care Health98.05%PACSPACS GroupN/ARDNTRadNet77.90%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipOPCHOption Care Health1.70%PACSPACS Group70.40%RDNTRadNet5.60%VRDNViridian Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPCHOption Care Health8,266157.03 million154.36 millionOptionablePACSPACS Group47,455157.16 million46.52 millionOptionableRDNTRadNet11,26478.27 million73.89 millionOptionableVRDNViridian Therapeutics50103.07 million100.60 millionOptionableVRDN, PACS, RDNT, and OPCH HeadlinesRecent News About These CompaniesEarnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates4 hours ago | finance.yahoo.comWhy Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising4 hours ago | finance.yahoo.comQ2 EPS Forecast for Viridian Therapeutics Boosted by AnalystMay 8 at 7:36 AM | marketbeat.comViridian Therapeutics' (VRDN) "Buy" Rating Reiterated at Needham & Company LLCMay 8 at 6:07 AM | americanbankingnews.comBrokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $37.07May 8 at 4:35 AM | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Sees Large Volume Increase - Time to Buy?May 7 at 5:38 PM | marketbeat.comViridian (VRDN) Climbs 33% on Looming Drug CommercializationMay 7 at 1:49 AM | finance.yahoo.comViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350 ...May 7 at 1:49 AM | finance.yahoo.comViridian Therapeutics prices upsized $350M concurrent stock and convertible notes offeringsMay 7 at 1:49 AM | msn.comViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionMay 6 at 11:13 PM | businesswire.comViridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLCMay 6 at 8:26 AM | marketbeat.comPrivium Fund Management B.V. Acquires Shares of 173,516 Viridian Therapeutics, Inc. $VRDNMay 6 at 6:47 AM | marketbeat.comViridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TEDMay 6 at 4:23 AM | marketbeat.comViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye DiseaseMay 5 at 7:42 PM | timesargus.comTPDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 ResultsMay 5 at 7:42 PM | finance.yahoo.comViridian eye disease drug surpasses expectations in late-stage trial; shares soarMay 5 at 7:42 PM | msn.comVRDN stock records biggest single day gains in 45 months – and it’s not just due to a better-than-feared Q1 lossMay 5 at 7:42 PM | msn.comViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease TranscriptMay 5 at 6:07 PM | seekingalpha.comViridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred StockMay 5 at 4:05 PM | businesswire.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Up on Strong EarningsMay 5 at 10:25 AM | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Issues Earnings ResultsMay 5 at 8:48 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRDN, PACS, RDNT, and OPCH Company DescriptionsOption Care Health NASDAQ:OPCH$20.51 -0.24 (-1.16%) Closing price 04:00 PM EasternExtended Trading$20.51 0.00 (0.00%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.PACS Group NYSE:PACS$33.58 -0.05 (-0.13%) Closing price 03:58 PM EasternExtended Trading$34.08 +0.49 (+1.47%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.RadNet NASDAQ:RDNT$58.19 +0.69 (+1.20%) Closing price 04:00 PM EasternExtended Trading$60.52 +2.33 (+4.00%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Viridian Therapeutics NASDAQ:VRDN$16.61 -0.39 (-2.29%) Closing price 04:00 PM EasternExtended Trading$16.60 0.00 (-0.03%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
